ファーマコゲノミクス技術市場レポート：2030年までの動向、予測、競合分析

ファーマコゲノミクス技術の動向と予測

世界のファーマコゲノミクス技術市場は、2024年から2030年までのCAGRが6.7%で、2030年までに推定124億米ドルに達すると予想されています。この市場の主な促進要因は、ゲノミクス分野における遺伝子の違いの解明とそれが薬物反応性に及ぼす影響の大幅な進展、慢性疾患の増加による個別化治療のニーズの高まり、ゲノム配列決定のコスト低下と技術の進歩です。世界のファーマコゲノミクス技術市場の将来は、腫瘍、神経疾患、循環器疾患、免疫疾患、感染症市場に機会があり、有望視されています。

ファーマコゲノミクス技術市場の洞察

Lucintelは、PCRは特定のDNA配列の増幅を可能にするため、遺伝子型判定や薬物反応に関連する遺伝子変異の決定に不可欠なツールであり、薬効や代謝に影響を与える遺伝子変化や一塩基多型（SNP）を見つけるために頻繁に使用されることから、予測期間中も最大セグメントであり続けると予測しています。

北米は、この分野で著名な企業の存在、有利な保険償還規則、治療改善のための早期診断の重要性に対する意識の高まり、この地域の整備されたヘルスケアインフラなどの理由から、予測期間中も最大の地域であり続けると思われます。

よくある質問

Q1.市場規模は？

A1.世界のファーマコゲノミクス技術市場は、2030年までに推定124億米ドルに達すると予想されています。

Q2.市場の成長予測は？

A2.世界のファーマコゲノミクス技術市場は、2024年から2030年にかけてCAGR 6.7%で成長する見込みです。

Q3.市場の成長に影響を与える主な促進要因は？

A3.この市場の主な促進要因は、ゲノミクス分野における遺伝的差異の解明とそれが薬物反応性に及ぼす影響の大幅な進展、慢性疾患の増加による個別化治療のニーズの高まり、ゲノム配列決定のコスト低下と技術の進歩です。

Q4.市場の主要セグメントは？

A4.世界のファーマコゲノミクス技術市場の将来は、腫瘍、神経疾患、循環器疾患、免疫疾患、感染症市場に機会があり、有望です。

Q5.市場の主要企業は？

A5.主要なファーマコゲノミクス技術企業は以下の通りです。

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Q6.今後、最大となる市場セグメントは？

A6.Lucintelは、PCRは特定のDNA配列の増幅を可能にし、遺伝子型判定や薬物反応に関連する遺伝子変異の決定に不可欠なツールであり、薬効や代謝に影響を与える遺伝子変化や一塩基多型（SNP）を見つけるために頻繁に使用されるため、予測期間中も最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は？

A7.北米は、この分野で著名な企業の存在、有利な償還規則、治療改善のための早期診断の重要性に対する意識の高まり、この分野のヘルスケアインフラが発達していることなどから、予測期間を通じて最大の地域であり続けると思われます。

Q8.レポートのカスタマイズは可能？

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のファーマコゲノミクス技術市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界のファーマコゲノミクス技術市場動向（2018-2023）と予測（2024-2030）
• 技術別の世界のファーマコゲノミクス技術市場
  • PCR
  • In situ ハイブリダイゼーション
  • 免疫組織化学
  • シーケンス
  • その他
• 治療領域別の世界のファーマコゲノミクス技術市場
  • 腫瘍
  • 神経疾患
  • 循環器疾患
  • 免疫疾患
  • 感染症
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界のファーマコゲノミクス技術市場
• 北米のファーマコゲノミクス技術市場
• 欧州のファーマコゲノミクス技術市場
• アジア太平洋のファーマコゲノミクス技術市場
• その他地域のファーマコゲノミクス技術市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 技術別の世界のファーマコゲノミクス技術市場の成長機会
  • 治療領域別の世界のファーマコゲノミクス技術市場の成長機会
  • 地域別の世界のファーマコゲノミクス技術市場の成長機会
• 世界のファーマコゲノミクス技術市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界のファーマコゲノミクス技術市場の能力拡大
  • 世界のファーマコゲノミクス技術市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Pharmacogenomics Technology Trends and Forecast

The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

A more than 150-page report is developed to help in your business decisions.

Pharmacogenomics Technology by Segment

The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.

Pharmacogenomics Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Pharmacogenomics Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Pharmacogenomics Technology Market Insights

Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Features of the Global Pharmacogenomics Technology Market

Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).

Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the pharmacogenomics technology market size?

Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.

Q2. What is the growth forecast for pharmacogenomics technology market?

Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?

Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

Q4. What are the major segments for pharmacogenomics technology market?

Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.

Q5. Who are the key pharmacogenomics technology market companies?

Answer: Some of the key pharmacogenomics technology companies are as follows.

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Q6. Which pharmacogenomics technology market segment will be the largest in future?

Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the pharmacogenomics technology market by technology (PCR, in-situ hybridization, immunohistochemistry, sequencing, and others), therapeutic area (oncology, neurological disorders, cardiovascular disease, immunological disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pharmacogenomics Technology Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Pharmacogenomics Technology Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Pharmacogenomics Technology Market by Technology
  • 3.3.1: PCR
  • 3.3.2: In-situ Hybridization
  • 3.3.3: Immunohistochemistry
  • 3.3.4: Sequencing
  • 3.3.5: Others
• 3.4: Global Pharmacogenomics Technology Market by Therapeutic Area
  • 3.4.1: Oncology
  • 3.4.2: Neurological Disorders
  • 3.4.3: Cardiovascular Disease
  • 3.4.4: Immunological Disorders
  • 3.4.5: Infectious Diseases
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Pharmacogenomics Technology Market by Region
• 4.2: North American Pharmacogenomics Technology Market
  • 4.2.2: North American Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.3: European Pharmacogenomics Technology Market
  • 4.3.1: European Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.3.2: European Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.4: APAC Pharmacogenomics Technology Market
  • 4.4.1: APAC Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.4.2: APAC Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
• 4.5: ROW Pharmacogenomics Technology Market
  • 4.5.1: ROW Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
  • 4.5.2: ROW Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Pharmacogenomics Technology Market by Technology
  • 6.1.2: Growth Opportunities for the Global Pharmacogenomics Technology Market by Therapeutic Area
  • 6.1.4: Growth Opportunities for the Global Pharmacogenomics Technology Market by Region
• 6.2: Emerging Trends in the Global Pharmacogenomics Technology Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Pharmacogenomics Technology Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pharmacogenomics Technology Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GE HealthCare
• 7.2: Agilent Technologies
• 7.3: F. Hoffmann-La Roche
• 7.4: FOUNDATION MEDICINE
• 7.5: Thermo Fisher Scientific
• 7.6: Leica Biosystems Nussloch
• 7.7: Pfizer